Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cathy Chen

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Journal of Arrhythmia|January 16, 2025
Two-year clinical outcomes of Taiwanese and other Asian ethnicities with atrial fibrillation treated with edoxaban in the ETNA-AF Asia registryChun-Chieh Wang, Cheng-I Cheng, Kwo-Chang Ueng, et al.
JACC. Cardiovascular Interventions|February 11, 2026
Major Bleeding Risk Assessment With Atrial Fibrillation Post-TAVR: The HARHP Score Results From ENVISAGE-TAVI AFGeorge D Dangas, Martin Unverdorben, Christian Hengstenberg, et al.
Research Square|June 12, 2025
Host-Derived Geranylgeraniol Shields Intraerythrocytic Stages of Malaria Parasites from FosmidomycinIgnasi Verdaguer, Cathy Chen, Maurício Mazzine Filho, et al.
Clinical Cardiology|October 26, 2019
The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and designRaffaele De Caterina, Giancarlo Agnelli, Petra Laeis, et al.
JACC. Advances|June 28, 2024
Sex Differences Among Patients Receiving Edoxaban vs Vitamin K Antagonist for Atrial Fibrillation After TAVRRoxana Mehran, Alessandro Spirito, James Jin, et al.
Frontiers in Pharmacology|February 9, 2026
Edoxaban for stroke prevention in Chinese patients with atrial fibrillation: 1-year follow-up of the ETNA-AF-China studyXueyuan Guo, Juan Du, Yuehui Yin, et al.
Scientific Reports|February 2, 2024
Edoxaban for stroke prevention in atrial fibrillation and factors associated with dosing: patient characteristics from the prospective observational ETNA-AF-China registryXueyuan Guo, Juan Du, Yang Yang, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|August 14, 2022
Edoxaban vs. Vitamin K Antagonist for Atrial Fibrillation After Transcatheter Aortic Valve Replacement in Japanese Patients - A Subanalysis of the ENVISAGE-TAVI AF TrialYusuke Watanabe, Kentaro Hayashida, Masanori Yamamoto, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 2, 2003
A strabismus susceptibility locus on chromosome 7pVaishali Parikh, Yin Yao Shugart, Kimberly F Doheny, et al.
Journal of the American Heart Association|February 15, 2018
Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think TankRachel D Torok, Jennifer S Li, Prince J Kannankeril, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Journal of Arrhythmia|January 16, 2025
Two-year clinical outcomes of Taiwanese and other Asian ethnicities with atrial fibrillation treated with edoxaban in the ETNA-AF Asia registryChun-Chieh Wang, Cheng-I Cheng, Kwo-Chang Ueng, et al.
JACC. Cardiovascular Interventions|February 11, 2026
Major Bleeding Risk Assessment With Atrial Fibrillation Post-TAVR: The HARHP Score Results From ENVISAGE-TAVI AFGeorge D Dangas, Martin Unverdorben, Christian Hengstenberg, et al.
Research Square|June 12, 2025
Host-Derived Geranylgeraniol Shields Intraerythrocytic Stages of Malaria Parasites from FosmidomycinIgnasi Verdaguer, Cathy Chen, Maurício Mazzine Filho, et al.
Clinical Cardiology|October 26, 2019
The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and designRaffaele De Caterina, Giancarlo Agnelli, Petra Laeis, et al.
JACC. Advances|June 28, 2024
Sex Differences Among Patients Receiving Edoxaban vs Vitamin K Antagonist for Atrial Fibrillation After TAVRRoxana Mehran, Alessandro Spirito, James Jin, et al.
Frontiers in Pharmacology|February 9, 2026
Edoxaban for stroke prevention in Chinese patients with atrial fibrillation: 1-year follow-up of the ETNA-AF-China studyXueyuan Guo, Juan Du, Yuehui Yin, et al.
Scientific Reports|February 2, 2024
Edoxaban for stroke prevention in atrial fibrillation and factors associated with dosing: patient characteristics from the prospective observational ETNA-AF-China registryXueyuan Guo, Juan Du, Yang Yang, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|August 14, 2022
Edoxaban vs. Vitamin K Antagonist for Atrial Fibrillation After Transcatheter Aortic Valve Replacement in Japanese Patients - A Subanalysis of the ENVISAGE-TAVI AF TrialYusuke Watanabe, Kentaro Hayashida, Masanori Yamamoto, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 2, 2003
A strabismus susceptibility locus on chromosome 7pVaishali Parikh, Yin Yao Shugart, Kimberly F Doheny, et al.
Journal of the American Heart Association|February 15, 2018
Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think TankRachel D Torok, Jennifer S Li, Prince J Kannankeril, et al.
Pageof 7